StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Korsana Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.60M, up 597.4% year over year. For fiscal 2025 it was $959.00K, up 235.3% from the year before. The highest annual figure on record is $95.14M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$959.00K+235.3%
FY2024Dec 31, 2024$286.00K-81.1%
FY2023Dec 31, 2023$1.52M-74.7%
FY2022Dec 31, 2022$5.98M-84.1%
FY2021Dec 31, 2021$37.64M-33.3%
FY2020Dec 31, 2020$56.41M-40.7%
FY2019Dec 31, 2019$95.14M+8.5%
FY2018Dec 31, 2018$87.72M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$730.00K+1927.8%
Q4 FY2025Dec 31, 2025$519.00K+826.8%
Q3 FY2025Sep 30, 2025$348.00K+329.6%
Q2 FY2025Jun 30, 2025$56.00K-46.7%
Q1 FY2025Mar 31, 2025$36.00K-18.2%
Q4 FY2024Dec 31, 2024$56.00K+133.3%
Q3 FY2024Sep 30, 2024$81.00K-86.0%
Q2 FY2024Jun 30, 2024$105.00K-69.0%
Q1 FY2024Mar 31, 2024$44.00K-92.3%
Q4 FY2023Dec 31, 2023$24.00K-98.0%
Q3 FY2023Sep 30, 2023$580.00K-59.0%
Q2 FY2023Jun 30, 2023$339.00K-96.7%
Q1 FY2023Mar 31, 2023$572.00K-94.1%
Q4 FY2022Dec 31, 2022$1.18M-88.8%
Q3 FY2022Sep 30, 2022$1.41M-79.9%
Q2 FY2022Jun 30, 2022$10.22M-15.2%
Q1 FY2022Mar 31, 2022$9.74M+20.4%
Q4 FY2021Dec 31, 2021$10.46M-13.5%
Q3 FY2021Sep 30, 2021$7.03M-48.7%
Q2 FY2021Jun 30, 2021$12.05M-12.6%
Q1 FY2021Mar 31, 2021$8.09M-51.9%
Q4 FY2020Dec 31, 2020$12.09M-41.5%
Q3 FY2020Sep 30, 2020$13.70M-38.5%
Q2 FY2020Jun 30, 2020$13.79M-46.4%
Q1 FY2020Mar 31, 2020$16.83M-36.3%
Q4 FY2019Dec 31, 2019$20.68M-7.9%
Q3 FY2019Sep 30, 2019$22.30M+3.7%
Q2 FY2019Jun 30, 2019$25.76M+15.8%
Q1 FY2019Mar 31, 2019$26.40M+22.7%
Q4 FY2018Dec 31, 2018$22.45M–
Q3 FY2018Sep 30, 2018$21.50M–
Q2 FY2018Jun 30, 2018$22.25M–
Q1 FY2018Mar 31, 2018$21.51M–

More Korsana Biosciences figures

See a number that looks wrong?